Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a pharmaceutical company with a market capitalization of $34.8 billion and an impressive 80% return over the past year, announced significant updates following its 2025 Annual Meeting of Stockholders held on May 8, 2025. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. The company reported the approval of a Certificate of Amendment to the Restated Certificate of Incorporation, enabling officer exculpation, which became effective immediately upon filing with the Delaware Secretary of State.
During the Annual Meeting, stockholders re-elected four Class III directors to serve until the 2028 annual meeting. The directors re-elected were Carolyn R. Bertozzi, Ph.D., Margaret A. Hamburg, M.D., Colleen F. Reitan, and Amy W. Schulman. The meeting also saw the ratification of PricewaterhouseCoopers LLP as the company’s independent auditors for the fiscal year ending December 31, 2025.
Additionally, Alnylam’s stockholders approved the Second Amended and Restated 2018 Stock Incentive Plan and, in a non-binding advisory vote, endorsed the compensation of the company’s named executive officers.
The company, headquartered in Cambridge, Massachusetts, and incorporated in Delaware, specializes in pharmaceutical preparations. Alnylam Pharmaceuticals continues to focus on the development of RNA interference (RNAi) therapeutics, and these corporate governance updates are part of the company’s ongoing efforts to align with stockholder interests and regulatory requirements.
This report is based on a press release statement and the information filed with the SEC.
In other recent news, Alnylam Pharmaceuticals announced its Q1 2025 earnings, reporting a significant earnings per share (EPS) beat with -0.01 against a forecast of -0.93. The company also exceeded revenue projections, achieving $594.19 million compared to an anticipated $588.75 million, marking a 28% year-over-year growth. H.C. Wainwright reaffirmed its Buy rating on Alnylam stock, citing the strong performance of AMVUTTRA (vutrisiran) as a key factor, and set a price target of $500. The firm noted a 45% year-over-year increase in U.S. TTR revenues, reaching $359 million, with AMVUTTRA being chosen by approximately 70% of new patients starting treatment for hereditary ATTR with polyneuropathy (hATTR-PN).
Alnylam also maintained its 2025 financial guidance, projecting product revenues between $2.05 billion and $2.25 billion, aligning closely with analyst estimates. The company expressed confidence in achieving sustainable non-GAAP operating profitability within the year. Additionally, Alnylam has been preparing for several clinical programs, including the Phase 3 TRITON-CM trial for nucresiran in ATTR amyloidosis and a cardiovascular outcomes trial for zilebesiran in hypertension.
Moreover, Alnylam plans to present new data from its transthyretin amyloidosis (TTR) programs at the Heart Failure 2025 Congress. This includes findings from the HELIOS-B Phase 3 study on vutrisiran, which has recently gained approvals in the U.S. and Brazil and received a positive opinion from the European Medicines Agency. The company also discussed the design of the TRITON-CM Phase 3 study of nucresiran, a next-generation TTR silencer for patients with ATTR-CM.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.